Stay updated with breaking news from Nasdaq Cmpx. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Compass Therapeutics, Inc. (NASDAQ:CMPX – Get Rating) CEO Thomas J. Schuetz acquired 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 21st. The shares were bought at an average price of $2.80 per share, with a total value of $56,000.00. Following the completion of the transaction, the chief executive officer […]
Compass Therapeutics, Inc. (NASDAQ:CMPX – Get Rating) saw a large decrease in short interest during the month of May. As of May 31st, there was short interest totalling 157,100 shares, a decrease of 32.1% from the May 15th total of 231,400 shares. Currently, 0.3% of the company’s stock are short sold. Based on an average […]
Compass Therapeutics, Inc. (NASDAQ:CMPX – Get Rating) CEO Thomas J. Schuetz bought 30,000 shares of the company’s stock in a transaction that occurred on Monday, June 13th. The shares were purchased at an average price of $2.29 per share, with a total value of $68,700.00. Following the transaction, the chief executive officer now directly owns […]
Small-cap stocks are usually young companies that present significant growth potential, but they are less stable than large-cap stocks. However, a com
Equities analysts expect that Compass Therapeutics, Inc. (NASDAQ:CMPX – Get Rating) will announce earnings per share (EPS) of ($0.09) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Compass Therapeutics’ earnings, with estimates ranging from ($0.14) to ($0.06). The firm is expected to report its next earnings report on Monday, […]